Simplex Trading’s Unity Biotechnology UBX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,100
| Closed | -$2K | – | 9783 |
|
|
2025
Q1 | $2K | Buy |
+2,100
| New | +$3.79K | ﹤0.01% | 8091 |
|
|
2023
Q4 | – | Sell |
-500
| Closed | -$1K | – | 9870 |
|
|
2023
Q3 | $1K | Sell |
500
-200
| -29% | -$530 | ﹤0.01% | 8437 |
|
|
2023
Q2 | $1K | Sell |
700
-5,600
| -89% | -$14.8K | ﹤0.01% | 8741 |
|
|
2023
Q1 | $10K | Buy |
6,300
+5,800
| +1,160% | +$23.2K | ﹤0.01% | 7572 |
|
|
2022
Q4 | $1K | Buy |
500
+80
| +19% | +$232 | ﹤0.01% | 8947 |
|
|
2022
Q3 | $1K | Sell |
420
-510
| -55% | -$3.22K | ﹤0.01% | 9658 |
|
|
2022
Q2 | $5K | Buy |
930
+10
| +1% | +$83 | ﹤0.01% | 8871 |
|
|
2022
Q1 | $10K | Sell |
920
-960
| -51% | -$10.8K | ﹤0.01% | 8902 |
|
|
2021
Q4 | $27K | Buy |
1,880
+350
| +23% | +$7.65K | ﹤0.01% | 8044 |
|
|
2021
Q3 | $68K | Buy |
1,530
+220
| +17% | +$7.76K | ﹤0.01% | 7130 |
|
|
2021
Q2 | $60K | Buy |
1,310
+1,300
| +13,000% | +$62.6K | ﹤0.01% | 7435 |
|
|
2021
Q1 | $58K | Buy |
+10
| New | +$682 | ﹤0.01% | 6430 |
|
|
2020
Q2 | – | Hold |
0
| – | -$1K | – | 8397 |
|
|
2020
Q1 | – | Sell |
-1
| Closed | -$63 | – | 7417 |
|
|
2019
Q4 | $4K | Buy |
+1
| New | +$71 | ﹤0.01% | 6810 |
|
Simplex Trading's UBX Position: Q4 2025 in Review
Simplex Trading sold out of Unity Biotechnology (UBX) in Q4 2025, closing a stake of 2,571 shares.
Simplex Trading first reported a position in UBX in Q1 2019 and held it in 15 quarters. The position peaked at $133K in Q4 2021. 0 funds tracked by Wall St. Rank hold UBX as of Q4 2025.
- Simplex Trading reported no remaining Unity Biotechnology position as of Q4 2025 after selling out during the quarter.
- Simplex Trading sold 2,571 Unity Biotechnology shares in Q4 2025.
- Simplex Trading first reported a position in Unity Biotechnology in Q1 2019 and held it in 15 quarters.
- Simplex Trading's Unity Biotechnology position peaked at $133K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2025.
Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.